POZZI, ELEONORA
 Distribuzione geografica
Continente #
NA - Nord America 12.485
AS - Asia 9.270
EU - Europa 6.380
SA - Sud America 1.043
Continente sconosciuto - Info sul continente non disponibili 943
AF - Africa 197
OC - Oceania 43
Totale 30.361
Nazione #
US - Stati Uniti d'America 11.822
SG - Singapore 2.706
VN - Vietnam 2.462
IT - Italia 2.032
CN - Cina 1.789
DE - Germania 962
HK - Hong Kong 897
RU - Federazione Russa 853
BR - Brasile 790
SE - Svezia 557
CA - Canada 531
GB - Regno Unito 391
IE - Irlanda 352
FR - Francia 259
IN - India 257
KR - Corea 215
BD - Bangladesh 188
FI - Finlandia 176
ID - Indonesia 136
AT - Austria 133
NL - Olanda 112
UA - Ucraina 101
JP - Giappone 100
AR - Argentina 96
TR - Turchia 93
IQ - Iraq 82
LT - Lituania 75
DK - Danimarca 74
ES - Italia 73
MX - Messico 62
PL - Polonia 55
PK - Pakistan 54
CH - Svizzera 52
ZA - Sudafrica 52
SA - Arabia Saudita 44
AU - Australia 40
EG - Egitto 39
EC - Ecuador 38
BE - Belgio 36
CO - Colombia 33
MY - Malesia 33
PH - Filippine 31
VE - Venezuela 28
TW - Taiwan 23
PY - Paraguay 22
MA - Marocco 20
RO - Romania 20
IR - Iran 18
TH - Thailandia 18
AE - Emirati Arabi Uniti 17
ET - Etiopia 16
UZ - Uzbekistan 16
CL - Cile 14
CZ - Repubblica Ceca 13
KZ - Kazakistan 13
DZ - Algeria 12
JM - Giamaica 12
JO - Giordania 12
OM - Oman 12
CR - Costa Rica 11
HN - Honduras 11
IL - Israele 11
TN - Tunisia 11
KE - Kenya 10
BO - Bolivia 9
PS - Palestinian Territory 9
UY - Uruguay 8
AO - Angola 7
EU - Europa 7
RS - Serbia 7
AZ - Azerbaigian 6
BG - Bulgaria 6
HR - Croazia 6
NG - Nigeria 6
NI - Nicaragua 6
NP - Nepal 6
HU - Ungheria 5
PA - Panama 5
AL - Albania 4
BN - Brunei Darussalam 4
GR - Grecia 4
GT - Guatemala 4
KG - Kirghizistan 4
LV - Lettonia 4
NO - Norvegia 4
PE - Perù 4
SN - Senegal 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
BB - Barbados 3
BH - Bahrain 3
DO - Repubblica Dominicana 3
KW - Kuwait 3
LY - Libia 3
MD - Moldavia 3
MU - Mauritius 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
SC - Seychelles 3
SK - Slovacchia (Repubblica Slovacca) 3
Totale 29.393
Città #
Ann Arbor 1.752
Singapore 1.620
Dallas 1.531
Ashburn 996
San Jose 947
Hong Kong 863
Milan 780
Ho Chi Minh City 744
Hanoi 593
Frankfurt am Main 567
Toronto 380
Los Angeles 360
Wilmington 348
Dublin 340
New York 330
Chandler 320
Council Bluffs 292
Beijing 252
Santa Clara 244
Dearborn 229
Hefei 195
Chicago 192
Seoul 177
Munich 165
Houston 160
Woodbridge 152
Boardman 146
Columbus 138
Princeton 136
Rome 132
Fairfield 130
The Dalles 130
Nanjing 119
Helsinki 115
Vienna 110
Buffalo 105
Jakarta 101
Lauterbourg 93
Seattle 92
Shanghai 92
Moscow 91
Orem 82
Da Nang 81
Jacksonville 81
São Paulo 79
Guangzhou 76
Haiphong 66
Tokyo 60
Vilnius 58
Ha Long 56
Hải Dương 53
Phoenix 52
Denver 51
Basingstoke 49
Chennai 49
Dong Ket 49
Montreal 48
Brooklyn 47
London 46
Biên Hòa 45
Amsterdam 43
Baghdad 43
Warsaw 43
Atlanta 41
Carate Brianza 38
Zurich 38
Ninh Bình 36
Pune 36
Rio de Janeiro 36
Bắc Ninh 35
Can Tho 35
Nuremberg 34
Quận Bình Thạnh 34
Poplar 33
Lawrence 32
Stockholm 32
Kent 31
Cambridge 30
Nanchang 30
Shenyang 30
Vũng Tàu 30
Altamura 28
San Francisco 28
Hangzhou 27
Melzo 27
Mexico City 26
Turku 26
Manchester 25
Thái Nguyên 25
Florence 24
Bắc Giang 23
Sacramento 23
Washington 23
Johannesburg 22
Baltimore 21
Brussels 21
Falls Church 21
Lappeenranta 21
Ottawa 21
Shangdi 21
Totale 18.580
Nome #
CIPN and its mechanism of development 649
Paclitaxel alters the microvascular network in the central and peripheral nervous system of rats with chemotherapy-induced painful peripheral neuropathy 590
Morphofunctional characterisation of axonal damage in different rat models of chemotherapy-induced peripheral neurotoxicity: the role of nerve excitability testing 517
Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity 475
Angiogenesis-Related New Mechanisms for Chemotherapy-Induced Painful Peripheral Neuropathy in the Rat 461
Effect of age on metabolomic changes in a model of paclitaxel‐induced peripheral neurotoxicity 461
Peripheral neuropathy induced by microtubule-targeted chemotherapies: Insights into acute injury and long-term recovery 460
High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats 442
Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights 440
Oxaliplatin-induced peripheral neurotoxicity: molecular insights 434
Role of Organic Transporters 1 and 2 in Cisplatin mediated neurotoxicity 422
Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity 410
Effect of age on metabolomic changes in a model of paclitaxel-induced neurotoxicity 410
OXALIPLATIN-INDUCED PERIPHERAL NEUROTOXICITY IN MOUSE MODELS: DIFFERENT TREATMENT SCHEDULES AND FOCUS ON OXIDATIVE STRESS 409
Ion Channel and Transporter Involvement in Chemotherapy-Induced Peripheral Neurotoxicity 404
The relevance of multimodal assessment in experimental oxaliplatin-induced peripheral neurotoxicity 403
Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity 395
Calmangafodipir reduces sensory alterations and prevents intraepidermal nerve fibers loss in a mouse model of oxaliplatin induced peripheral neurotoxicity 391
Investigation of Supraspinal Plasticity in a Rat Model of Painful Paclitaxel-induced Peripheral Neuropathy 386
ITF6475, a New Histone Deacetylase 6 Inhibitor, Prevents Painful Neuropathy Induced by Paclitaxel 383
CENTRAL AND PERIPHERAL MICROVASCULAR NETWORK IS ABNORMAL IN RATS WITH PAINFUL-CHEMOTHERAPY INDUCED NEUROPATHY: NEW PATHOPHYSIOLOGICAL MECHANISMS OVER THE HORIZON? 371
Givinostat-Liposomes: Anti-Tumor Effect on 2D and 3D Glioblastoma Models and Pharmacokinetics 362
Oxaliplatin-induced neuropathy occurs through impairment of haemoglobin proton buffering and is reversed by carbonic anhydrase inhibitors 349
Translation of paclitaxel-induced peripheral neurotoxicity from mice to patients: the importance of model selection 344
Molsidomine provides neuroprotection against vincristine-induced peripheral neurotoxicity through soluble guanylyl cyclase activation 339
Molsidomine reduces the severity of Vincristine-induced peripheral neurotoxicity in rats 336
Dorsal Root Ganglia Neurons Morphometry Analysing Method Optimization 333
The validation of neuroactive drug selection based on combinatorial screening in bortezomib-induced neurotoxicity models. 333
Neuronopathies and polyneuropathies: a ready to use translational neurophysiological protocol in rodent models 332
Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain 331
Sodium-Calcium Exchanger 2: A Pivotal Role in Oxaliplatin Induced Peripheral Neurotoxicity and Axonal Damage? 327
Paclitaxel, but Not Cisplatin, Affects Satellite Glial Cells in Dorsal Root Ganglia of Rats with Chemotherapy-Induced Peripheral Neurotoxicity 322
Assessment of oxaliplatin-induced peripheral neurotoxicity with different treatment schedules 320
Morpho-Functional Characterisation of the Rat Ventral Caudal Nerve in a Model of Axonal Peripheral Neuropathy 313
EVALUATION OF SATELLITE GLIAL CELLS CHANGES IN DORSAL ROOT GANGLIA IN CHEMOTHERAPY-INDUCED NEUROTOXICITY MODELS 312
Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy 310
An in vivo and in vitro neurophysiological approach to acute and chronic oxaliplatin-induced peripheral neurotoxicity 309
Sensory-motor paclitaxel polyneuropathy characterization in a rat model 305
Topiramate possible double efficacy profile: Oxaliplatin-induced peripheral neurotoxicity prevention and anticancer synergic action 304
Nerve Excitability Testing to Unravel Chemotherapy Induced Peripheral Neurotoxicity (CIPN) Pathogenesis: Altered Axonal Excitability as a Possible Pivotal Event Related to Platinum Compounds and Taxanes 303
In vivo study of Carfilzomib-Induced Neuropathy 295
NCX2 modulation to prevent axonal damage related to Oxaliplatin-induced peripheral neurotoxicity 288
Animal Models for the Study of Human Central and Peripheral Nervous System Diseases 288
Morphological and functional study of the caudal nerve in a rat model of peripheral neuropathy 285
Satellite Glial Cells in Chemotherapy Induced Peripheral Neuropathy 285
Reply to a comment paper on the published paper by canta, a. Et al: “calmangafodipir reduces sensory alterations and prevents intraepidermal nerve fibers loss in a mouse model of oxaliplatin induced peripheral neurotoxicity”—antioxidants 2020, 9, 594 283
Morphological and functional assessment of NCX2 potential role in axonal damage related to Oxaliplatin 282
Oxaliplatin induced peripheral neurotoxicity (OIPN) and ion unbalance: the perilous link between acute and chronic neurotoxicity. 279
MORPHOLOGICAL AND METABOLOMIC CHANGES IN PIPN 275
Multimodal experimental approach to the study of human neurological diseases 273
NEUROINFLAMMATION AS A POTENTIAL TARGET FOR CIPN DIAGNOSTIC AND TREATMENT 271
Central and peripheral neoangiogenesis in paclitaxel-induced painful peripheral neuropathy 269
Study of perpheral neurotoxicity of different doses of oxaliplatin in cd1 mice 267
Morphology meets function to unravel Oxaliplatin Induced Peripheral Neurotoxicity (OIPN) 264
USING A 3D APPROACH TO DESCRIBE CELL POPULATIONS IN THE RAT DORSAL ROOT GANGLIA 263
Studying the caudal nerve anatomy and physiology to refine detection of peripheral nerve damage in rodent models. 262
7T MRI first exploitation in a chemotherapy induced peripheral neurotoxicity in vivo model. 257
Paclitaxel alters angiogenesis in the peripheral and central nervous system of neuropathic rats 257
Genetic factors influencing the development of vincristine-induced neurotoxicity 254
Inhibition of NHE1 transport activity and gene transcription in DRG neurons in oxaliplatin-induced painful peripheral neurotoxicity 251
Ivig Effect In A Wistar Rat Model Of Bortezomib-Induced Peripheral Neuropathy 243
The relevance of morphology in experimental oxaliplatin-induced peripheral neurotoxicity 243
EVALUATION OF THE EFFICACY OF PERIPHAGEN NEUROTROPHIN-3 EXPRESSING VECTOR FOR OXALIPLATIN INDUCED PERIPHERAL NEUROPATHY. 242
Oxaliplatin neurotoxicity: morpho-functional approach 240
INVESTIGATING THE INVOLVEMENT OF SATELLITE GLIAL CELLS IN PACLITAXEL-INDUCED PERIPHERAL NEUROTOXICITY 240
Peripheral neurotoxicity induced by cisplatin: a possible role of OCT2 gene 238
ACCURATE NEUROPHYSIOLOGICAL MONITORING FOR SENSORY NEUROPATHY IN MOUSE MODELS OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROTOXICITY 236
Oxaliplatin-Induced Peripheral Neurotoxicity: Morphological Characterization In Different Mouse Strains 229
Metabolomics assessment in a mice model ofoxaliplatin-induced peripheral neurotoxicity 228
Intravenous Immunoglobulin Preparation Attenuates Pain Behaviors in a Wistar Rat Model of Bortezomib-Induced Peripheral Neuropathy 228
Acute and chronic Oxaliplatin-induced peripheral neurotoxicity: two sides of the same coin 225
Topiramate Prevents Oxaliplatin Neurotoxicity in a rat model 223
Effect of preventive and therapeutic treatment of ghrelin agonist HM01 on the peripheral neurotoxicity induced by bortezomib in wistar rats. 220
Blood neurofilament light chains as a potential damage marker in chemotherapy-induce peripheral neuropathy rodent models 220
Tackling Oxaliplatin Induced Peripheral neurotoxicity: from bed to bench side and back. 220
High resolution MRI in exploring peripheral nerve anatomy and axonal damage in rodent models 217
ERIBULIN, PACLITAXEL, IXABEPILONE AND VINORELBINE-INDUCED PERIPHERAL NEUROPATHY IN MICE: INSIGHTS IN LONG-TERM RECOVERY 216
Oxaliplatin induced peripheral neurotoxicity (OIPN): a translational approach for drug discovery. 216
NERVE EXCITABILITY TESTING AS THE LINK BETWEEN ANATOMY AND PHYSIOLOGY: AXONAL EXCITABILITY TESTING TO TEST IN VIVO MECHANISMS OF PERIPHERAL NERVE DAMAGE. 214
Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models 208
INVESTIGATION OF AGING EFFECTS ON NERVE DAMAGE IN AN ANIMAL MODEL OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY 208
The severity of oxaliplatin neurotoxicity is related to differential expression of a solute transporter in mice 206
Oxaliplatin Neurotoxicity is related to SLC4A1 Expression in BALB/c Mice Dorsal Root Ganglia 203
STANDARD AND ADVANCED NEUROPHYSIOLOGY SET UP IN MOUSE MODELS: SENSORY RECORDINGS AND NERVE EXCITABILITY TESTING OF THE CAUDAL NERVE. 193
Refinement Of Dorsal Root Ganglia Neurons Morphometry 192
An innovative traslational approach to oxaliplatin induced peripheral neurotoxicity in animal models: nerve excitability testing. 191
REFINEMENT OF MORPHOLOGICAL ANALYSIS OF THE CAUDAL NERVE IN A RODENT MODEL OF AXONAL DAMAGE WITH 7T MRI 186
Mitochondrial Dysfunction in Chemotherapy-Induced Peripheral Neuropathy (CIPN) 183
Neurofilament light protein: a blood biomarker of neurodegeneration in chemotherapy-induced peripheral neurotoxicity. 182
Topiramate neuroprotectant effects against oxaliplatin induced peripheral neurotoxicity 181
MORPHOFUNCTIONAL CHARACTERIZATION OF CIPN 173
Oxaliplatin induced Peripheral Neurotoxicity (OIPN): a Rat Model that full encompasses all OIPN Phenomena 171
Investigation of Supraspinal Plasticity of Painful Paclitaxel-Induced Peripheral Neuropathy 168
Nerve Excitability Testing: An In Vivo Translational Approach To Investigate Oxaliplatin Induced Peripheral Neurotoxicity Pathogenesis And Treatment 167
Oxaliplatin-Induced Peripheral Neurotoxicity: a Role for Genomics? 164
Oxaliplatin induced peripheral neurotoxicity: nerve excitability testing full profile in a long term toxicity animal study 161
Can different Mice Strains be differently susceptible to Oxaliplatin-Induced Peripheral Neuropathy? 155
New mechanisms of neurotoxicity related to oxaliplatin chemotherapy in mice 152
THYMOQUINONE AS A POSSIBLE NEUROPROTECTIVE AGENT AGAINST PACLITAXEL-INDUCED PERIPHERAL NEUROTOXICITY 149
Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity 143
Totale 29.019
Categoria #
all - tutte 91.022
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.022


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022995 0 133 110 97 93 104 49 49 44 52 79 185
2022/20231.860 187 364 234 172 163 300 63 75 135 41 82 44
2023/20241.550 68 61 70 92 156 356 242 104 77 39 47 238
2024/20255.175 239 500 470 235 401 282 434 186 577 708 406 737
2025/202614.780 2.206 1.468 1.975 1.298 1.163 669 1.721 641 983 1.102 745 809
2026/20271.271 775 496 0 0 0 0 0 0 0 0 0 0
Totale 30.361